XML 86 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Reporting
9 Months Ended 12 Months Ended
Sep. 30, 2019
Dec. 31, 2018
Segment Reporting [Abstract]    
Segment Reporting

NOTE 8 – SEGMENT REPORTING

 

The Company classifies its business interests into reportable segments which are Trxade, Community Specialty and Integra.

 

Nine Months Ended September 30, 2019   Trxade, Inc.     Community Specialty Pharmacy, LLC     Integra Pharma, LLC     Unallocated     Total  
Revenue   $ 3,335,050     $ 1,412,449     $ 992,862     $ -     $ 5,740,361  
Segment Assets   $ 1,561,760     $ 315,681       411,161     $ 3,565,921     $ 5,854,523  
Segment Profit/Loss   $ 1,748,896     $ (75,955 )   $ (122,144 )   $ (1,340,022 )   $ 210,775  

 

The Company had no reportable segments for the nine months ended September 30, 2018. See NOTE 9 – BUSINESS COMBINATION.

NOTE 11 – SEGMENT REPORTING

 

The Company classifies its business interests into reportable segments which are Trxade, Inc., Community Specialty Pharmacy, LLC, and Other. Operating segments are defined as the components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Our chief operating decision makers direct the allocation of resources to operating segments based on the profitability, cash flows, and growth opportunities of each respective segment.

 

Year Ended December 31, 2018   Trxade, Inc.     Community Specialty Pharmacy, LLC     Other  
Revenue   $ 3,407,822     $ 395,418     $ 28,538  
Gross Profit   $ 3,407,822     $ (34,971 )   $ 9,878  
Segment Assets   $ 822,412     $ 112,123     $ 1,293,052  
Segment Profit/Loss   $ 1,371,615     $ (116,588 )   $ (1,245,989 )

 

The Company had no reportable segments in 2017. See Note 12.